Durvalumab safety study for resectable lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tracks the safety of the drug durvalumab (an immunotherapy) in people with early-stage, operable lung cancer that is large or has spread to nearby lymph nodes. It aims to see how well the drug works in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with non-small cell lung cancer (NSCLC) that can be removed with surgery.
- Your tumor is at least 4 cm in size or has spread to nearby lymph nodes.
- Your cancer has not been previously treated with any therapy.
- You do not have certain genetic changes (EGFR mutations or ALK rearrangements) in your tumor.
- Your doctor has prescribed durvalumab as part of your treatment plan.
- You have not had durvalumab before for any other condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
This phase 2 study tests durvalumab plus IPH5201 given before surgery to improve outcomes for people with resectable non-small cell lung cancer. It aims to shrink or control the cancer and make surgery more effective, using information about specific tumor markers like PD-L1.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
This trial tests adding durvalumab (an immune therapy) to a radiation treatment plan for people with non-small cell lung cancer (NSCLC) who can’t safely have chemotherapy at the same time or surgery first. It aims to improve cancer control after radiation by helping the immune system recognize and fight the tumor.
This trial studies whether adding durvalumab (an immune therapy) to standard chemoradiation before surgery can improve outcomes for people with stage III, resectable lung cancer. It aims to help shrink the tumor and improve chances of successful treatment.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.